Lutetium-PSMA

PreclinicalRadiopharmaceutical

Lutetium-PSMA is one of 49 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerActive, not recruiting

Metastatic Prostate CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Metastatic Prostate Cancer

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

4 2

Xtandi

Astellas

Phase 3

20 3

Zytiga

Johnson & Johnson

Phase 3

20 4

Taxotere

AAvyxa

Phase 3

41 5

Talzenna

Balversa

Zoladex

TTerSera Therapeutics LLC

Approved

3 8

Erleada

Johnson & Johnson

Phase 3

13 9

Nubeqa

Bayer

Phase 3

9 10

Jevtana

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Not yet recruiting

Metastatic Prostate Cancer

NCT06430411

Clinical

Trials by Indication[1]

Metastatic Prostate Cancer1 trial

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study

Not yet recruiting·MMedical University of Vienna··NCT06430411·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lutetium-PSMA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lutetium-PSMA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lutetium-PSMA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Vienna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Vienna

Lutetium-PSMA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Metastatic Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News